Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant

Study Overview
=================
Brief Summary
-----------------
This is a phase 1, 2-part, open-label, fixed-sequence study evaluating the effect of rifampin (part 1) and rabeprazole (part 2) on the pharmacokinetics of a single dose of camlipixant (BLU-5937) 50 mg tablet in healthy participants under fasting conditions.

Official Title
-----------------
A Phase 1, 2-part, Open-label, Fixed-sequence Study Evaluating the Effect of Rifampin (Part 1) and Rabeprazole (Part 2) on the Pharmacokinetics of a Single Dose of Camlipixant (BLU-5937) 50 mg Tablet in Healthy Participants Under Fasting Conditions

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Camlipixant + Rifampin
* Drug: Camlipixant + Rabeprazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy males or non-pregnant, non-lactating healthy females Exclusion Criteria: History of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disorder, as judged by the investigator.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Rifampin effect on camlipixant pharmacokinetics<br> | Drug: Camlipixant + Rifampin<br>* Camlipixant will be administered alone as well as in co-administration with rifampin<br>|
| Experimental: Rabeprazole effect on camlipixant pharmacokinetics<br> | Drug: Camlipixant + Rabeprazole<br>* Camlipixant will be administered alone as well as in co-administration with rabeprazole<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of the area under the plasma concentration by time curve (AUC0-inf) | To assess the comparison between AUC0-inf following administration of camlipixant alone and after repeated oral doses of rifampin | Pre dose to up to 48 hours post-dose | 
| Measurement of the area under the plasma concentration by time curve (AUC0-t) | To assess the comparison between AUC0-t following administration of camlipixant alone and after repeated oral doses of rifampin | Pre dose to up to 48 hours post-dose | 
| Measurement of the maximum observed plasma drug concentration (Cmax) | To assess the comparison between Cmax following administration of camlipixant alone and after repeated oral doses of rifampin | Pre dose to up to 48 hours post-dose | 
| Measurement of the area under the plasma concentration by time curve (AUC0-inf) | To assess the comparison between AUC0-inf following administration of camlipixant alone and after repeated oral doses of rabeprazole | Pre dose to up to 48 hours post-dose | 
| Measurement of the area under the plasma concentration by time curve (AUC0-t) | To assess the comparison between AUC0-t following administration of camlipixant alone and after repeated oral doses of rabeprazole | Pre dose to up to 48 hours post-dose | 
| Measurement of the maximum observed plasma drug concentration (Cmax) | To assess the comparison between Cmax following administration of camlipixant alone and after repeated oral doses of rabeprazole | Pre dose to up to 48 hours post-dose |